ATE394372T1 - G-lactamderivate als prostaglandinagonisten - Google Patents

G-lactamderivate als prostaglandinagonisten

Info

Publication number
ATE394372T1
ATE394372T1 AT04737283T AT04737283T ATE394372T1 AT E394372 T1 ATE394372 T1 AT E394372T1 AT 04737283 T AT04737283 T AT 04737283T AT 04737283 T AT04737283 T AT 04737283T AT E394372 T1 ATE394372 T1 AT E394372T1
Authority
AT
Austria
Prior art keywords
inagonists
prostagland
lactam derivatives
lactam
derivatives
Prior art date
Application number
AT04737283T
Other languages
English (en)
Inventor
Gian Luca Araldi
Srinivasa Karra
Zhong Zhao
Nadia Brugger
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of ATE394372T1 publication Critical patent/ATE394372T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/2672-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT04737283T 2003-03-03 2004-03-02 G-lactamderivate als prostaglandinagonisten ATE394372T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45182903P 2003-03-03 2003-03-03

Publications (1)

Publication Number Publication Date
ATE394372T1 true ATE394372T1 (de) 2008-05-15

Family

ID=32962645

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04737283T ATE394372T1 (de) 2003-03-03 2004-03-02 G-lactamderivate als prostaglandinagonisten

Country Status (11)

Country Link
US (1) US7276531B2 (de)
EP (1) EP1603874B1 (de)
JP (1) JP4662926B2 (de)
AR (1) AR043450A1 (de)
AT (1) ATE394372T1 (de)
AU (1) AU2004216857A1 (de)
CA (1) CA2513652A1 (de)
DE (1) DE602004013559D1 (de)
ES (1) ES2305779T3 (de)
NO (1) NO20054441L (de)
WO (1) WO2004078103A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547685B2 (en) 2004-11-08 2009-06-16 Allergan, Inc. Therapeutic substituted pyrrolidone compounds
CA2610692C (en) 2005-06-03 2014-11-25 Ono Pharmaceutical Co., Ltd. Ep2 agonists which may have an ep3 agonistic effect for regeneration and/or protection of nerves
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US9109209B2 (en) 2011-09-08 2015-08-18 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
US9440919B2 (en) * 2012-07-19 2016-09-13 Cayman Chemical Company, Inc. Difluorolactam compositions for EP4-mediated osteo related diseases and conditions
US8962863B2 (en) * 2012-08-21 2015-02-24 Allergan, Inc. Process for the synthesis of substituted gamma lactams
ES2635635T3 (es) * 2013-03-15 2017-10-04 Cayman Chemical Company, Incorporated Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
JP6368351B2 (ja) 2013-03-15 2018-08-01 ケイマン ケミカル カンパニー, インコーポレーテッド ジフルオロラクタムアナログを合成する方法
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
EP3021879A2 (de) * 2013-07-19 2016-05-25 Cayman Chemical Company, Incorporated Verfahren, systeme und zusammensetzungen zur förderung der knochenwachstums
EP3487495A1 (de) 2016-07-21 2019-05-29 Unilever PLC Lactame zur verwendung bei der behandlung von hautkrankheiten
CN109475525A (zh) 2016-07-21 2019-03-15 荷兰联合利华有限公司 4-(4-氯苯基)-5-亚甲基-吡咯-2-酮和5-亚甲基-4-(对甲苯基)吡咯-2-酮用于治疗革兰氏阴性细菌感染
US10875830B2 (en) 2016-07-21 2020-12-29 Conopeo, Inc. Method of treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198503B (en) 1987-03-24 1989-10-30 Chinoin Gyogyszer Es Vegyeszet Process for producing triphenyl phosphonium salts
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
WO1999033794A1 (en) 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
EP1114816A4 (de) 1998-09-14 2002-09-04 Ono Pharmaceutical Co $g(v)-SUBSTITUIERTE PHENYL-PROSTAGLANDIN-E-DERIVATE UND SIE ALS AKTIVEN BESTANDTEIL ENTHALTENDE MEDIKAMENTE
US20010006980A1 (en) 1998-10-15 2001-07-05 Harada Shun-Ichi Methods for stimulating bone formation
EA005293B1 (ru) 1999-12-22 2004-12-30 Пфайзер Продактс Инк. Производные пирролидин-2-она и их применение при лечении остеопороза
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2002024647A1 (en) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
EA200300379A1 (ru) 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
RU2296122C2 (ru) * 2001-07-16 2007-03-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пирролидона в качестве простаноидных агонистов и фармацевтическая композиция
RU2288913C2 (ru) * 2001-07-16 2006-12-10 Ф.Хоффманн-Ля Рош Аг Аналоги простагландинов, способ их получения и фармацевтическая композиция, обладающая селективной агонистической активностью в отношении рецептора ep4

Also Published As

Publication number Publication date
ES2305779T3 (es) 2008-11-01
US7276531B2 (en) 2007-10-02
JP4662926B2 (ja) 2011-03-30
WO2004078103A2 (en) 2004-09-16
AU2004216857A1 (en) 2004-09-16
DE602004013559D1 (de) 2008-06-19
AR043450A1 (es) 2005-07-27
CA2513652A1 (en) 2004-09-16
JP2006519245A (ja) 2006-08-24
NO20054441L (no) 2005-09-26
WO2004078103A3 (en) 2004-10-28
EP1603874A2 (de) 2005-12-14
EP1603874B1 (de) 2008-05-07
US20060194865A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
ATE352550T1 (de) Chinazolinderivate
DK1682493T3 (da) Amidoacetonitrilderivater
DE602004018654D1 (de) Se
ATE363383T1 (de) Schlingenware
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
IS2656B (is) Nýjar besímídasólafleiður
AT502792A5 (de) Düsenanpressvorrichtung
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
DK1682129T3 (da) N-thiazol-2-ylbenzamidderivater
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
ATE449064T1 (de) Amidoacetonitrilderivate
ATA662003A (de) Trink-mundstück
IS8045A (is) Púrín-6-ón-afleiður
ATE444953T1 (de) Substituierte spirobenzazepine
DE60328233D1 (de) Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren
ATE406350T1 (de) Prolinylarylacetamide
AT500001B8 (de) Münzscheideeinrichtung
ATA1802003A (de) Verbundhonring
AT6592U3 (de) Frontgrubber

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties